Aurinia Pharmaceuticals Inc (AUPH) Upgraded to “Hold” by Zacks Investment Research
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Monday.
According to Zacks, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. “
A number of other research firms have also commented on AUPH. HC Wainwright boosted their price objective on Aurinia Pharmaceuticals from $8.00 to $12.00 and gave the stock a “positive” rating in a research note on Friday, March 3rd. FBR & Co reissued an “outperform” rating and issued a $9.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Thursday, February 9th. Canaccord Genuity reissued a “buy” rating and issued a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Friday, March 3rd. Finally, Leerink Swann boosted their price objective on Aurinia Pharmaceuticals from $7.00 to $11.00 and gave the stock an “outperform” rating in a research note on Thursday, March 2nd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Aurinia Pharmaceuticals has an average rating of “Buy” and a consensus price target of $8.92.
This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/20/aurinia-pharmaceuticals-inc-auph-upgraded-to-hold-by-zacks-investment-research.html
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) traded up 14.03% during trading on Monday, reaching $8.78. The company had a trading volume of 27,755,289 shares. Aurinia Pharmaceuticals has a 52-week low of $1.74 and a 52-week high of $10.54. The company has a 50 day moving average of $4.73 and a 200-day moving average of $3.34. The firm’s market capitalization is $469.10 million.
Your IP Address:
Institutional investors have recently bought and sold shares of the company. Acuta Capital Partners LLC acquired a new position in Aurinia Pharmaceuticals during the fourth quarter worth approximately $2,100,000. SG Americas Securities LLC acquired a new position in Aurinia Pharmaceuticals during the third quarter worth approximately $1,123,000. Redmile Group LLC raised its position in Aurinia Pharmaceuticals by 560.4% in the third quarter. Redmile Group LLC now owns 187,610 shares of the company’s stock worth $565,000 after buying an additional 159,200 shares in the last quarter. Oxford Asset Management acquired a new position in Aurinia Pharmaceuticals during the fourth quarter worth approximately $211,000. Finally, Creative Planning acquired a new position in Aurinia Pharmaceuticals during the third quarter worth approximately $181,000. 7.96% of the stock is currently owned by institutional investors.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.